Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test ®;Prévalence de Candida parapsilosis, C. orthopsilosis et de C. metapsilosis au sein des candidémies au CHU de Nantes et profil de sensibilité aux échinocandines par la méthode E-test ®: étude rétrospective de cinq ans (2004-2009)

Pathologie Biologie

Volumn 59, Issue 1, 2011, Pages 52-56

  Thierry, G ^a   Morio, F ^a,b   Le Pape, P ^a,b   Gay Andrieu, F ^a,b   Barre, O ^a   Miegeville, M ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

C. metapsilosis; C. orthopsilosis; Candida parapsilosis; Candidemia; E test ; Echinocandins; FKS1; Minimal inhibitory concentrations; Molecular identification; Prevalence

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; INTERNAL TRANSCRIBED SPACER; MICAFUNGIN; RIBOSOME DNA;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CONTROLLED STUDY; FRANCE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; GENE MUTATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FRANCE; FUNGAL PROTEINS; GLYCOSYLTRANSFERASES; HOSPITALS, UNIVERSITY; HUMANS; INFANT; INFANT, NEWBORN; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RIBOTYPING; SPECIES SPECIFICITY; YOUNG ADULT;

EID: 79951510868     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.07.019     Document Type: Article

References (24)

1. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
2. Trofa D., Gácser A., Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
3. Almirante B., Rodríguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006, 44:1681-1685.
4. Talarmin J., Boutoille D., Tattevin P., Dargère S., Weinbreck P., Ansart S., et al. Epidemiology of candidemia: a one-year prospective observational study in the west of France. Med Mal Infect 2009, 39:877-885.
5. Tavanti A., Davidson A.D., Gow N.A.R., Maiden M.C.J., Odds F.C. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005, 43:284-292.
6. Lockhart S.R., Messer S.A., Pfaller M.A., Diekema D.J. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008, 46:2659-2664.
7. Gomez-Lopez A., Alastruey-Izquierdo A., Rodriguez D., Almirante B., Pahissa A., Rodriguez-Tudela J.L., et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008, 52:1506-1509.
8. Silva A.P., Miranda I.M., Lisboa C., Pina-Vaz C., Rodrigues A.G. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009, 47:2392-2397.
9. Garcia-Effron G., Katiyar S.K., Park S., Edlind T.D., Perlin D.S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008, 52:2305-2312.
10. van Asbeck E., Clemons K.V., Martinez M., Tong A., Stevens D.A. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008, 62:106-109.
11. Orsi CF, Colombari B, Blasi E. Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex. Med Mycol 2010, [Epub ahead of print].
12. Morio F., Loge C., Besse B., Hennequin C., Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 2010, 66:373-384.
13. Desnos-Ollivier M., Dromer F., Dannaoui E. Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol 2008, 46:2389-2392.
14. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46:2620-2629.
15. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007, 10:121-130.
16. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
17. Horasan ES, Ersöz G, Göksu M, Otag F, Oner Kurt A, Karaçorlu S, et al. Increase in Candida parapsilosis Fungemia in critical care units: a 6-years study. Mycopathologia 2010, [Epub ahead of print].
18. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56:126-129.
19. Gonçalves SS, Amorim CS, Nucci M, Padovan ACB, Briones MRS, Melo ASA, et al. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 2009, [Epub ahead of print].
20. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
21. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377.
22. Espinel-Ingroff A., Canton E., Peman J., Martín-Mazuelo E. Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. Antimicrob Agents Chemother 2010, 54:1347-1350.
23. Arendrup M.C., Garcia-Effron G., Lass-Flörl C., Lopez A.G., Rodriguez-Tudela J., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010, 54:426-439.
24. Garcia-Effron G., Park S., Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009, 53:112-122.